An interventional study of Lembas Edge™ and Placebo in Appetite and Hunger, Suppression, Satiety and Appetite and Weight Change, sponsored by Lembas. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Lembas · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies in Body Weight Changes with a site in United States — 12 open to participants now, 17 under way, 2 of them phase 3. Body Weight Changes · United States.
Among the 113 studies in Body Weight Changes with a site in United States, this one is the 28th largest by planned enrollment of the 95 interventional ones that give a count, is one of 5 that started in 2026, is one of 73 with no phase, reaches primary completion later than 9 of the 16 other live ones, and was the 113th registered.
232 studies on the registry are indexed under Body Weight Changes; 31 are open to participants now.
Browse Body Weight Changes studies →12 of the 113 studies in Body Weight Changes with a site in United States are open now. Recruiting first, the newest first:
Viking Therapeutics, Inc. · Sites in United States
Ages 18+
Viking Therapeutics, Inc. · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 18+ · Healthy volunteers
Efforia, Inc · Sites in United States
Ages 18+ · Healthy volunteers
University of Illinois at Urbana-Champaign · Sites in United States
Ages 6–11 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 22 Body Weight Changes studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 10 · Phase 4 6
First in 2001; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 80 across 180 interventional studies indexed under Body Weight Changes.
Median enrollment 60 across the 95 interventional studies, 106 across the 17 observational. Of the 86 that completed or were terminated, 25 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 113 have an industry lead sponsor. The 10 most frequent:
Lembas is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Lembas has 1 study filed under Body Weight Changes — fewer than ten, so there is no comparison to draw.
8 of the studies in Body Weight Changes with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07556354University of Alabama at BirminghamEmpowering Faith-based Communities to Provide Personalized Diabetes Self-management Education and Support (DSMES) in the Magic City | 2026-11 |
| NCT06464497Vanderbilt UniversityWhole Foods for Teens: A Pilot Dietary Intervention to Reduce Body Adiposity in Adolescents With Obesity | 2026-12-31 |
| NCT06484114Fractyl Health Inc.Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide | 2027-02-15 |
| NCT07032571Stanford UniversityReset: Enhancing Weight Loss in a Digital Intervention | 2027-03 |
| NCT03085875Scripps Translational Science InstitutePOWERMOM, A Healthy Pregnancy Research Community | 2027-03-13 |
Add all 8 to your calendar (.ics) → With an account.
Among the 113 studies in Body Weight Changes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to see if a daily supplement called Lembas Edge™ helps control appetite and fullness in healthy adults who are overweight. The main questions it aims to answer are:
Researchers will compare two different doses of Lembas Edge™ to a placebo (a pill that looks identical but contains no active supplement) to see how well it works.
Participants will be asked to:
The rationale for this study is to observe safe, well-tolerated nutritional intervention that support appetite regulation, satiety, and long-term weight control. The current study aims to evaluate the impact of an investigational supplement, Lembas Edge™, on satiety-related outcomes and body weight relevant to weight management in overweight and mildly obese healthy adults. The safety profile will be measured via activities and technologies that can successfully and effectively be completed and utilized in a home setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
2a. Any therapies or treatments (pharmaceuticals, devices, supplements) within 90 days prior to randomization.
2b. Treatment with Glucagon-like peptide-1 (GLP-1) agonists (Semaglutide (Ozempic, Wegovy, Rybelsus), Tirzepatide (Mounjaro, Zepbound), Liraglutide (Victoza, Saxenda), Dulaglutide (Trulicity), Exenatide (Byetta, Bydureon BCise), Orforglipon, Cagrilintine/Semaglutide (CagriSema)) within the last 90 days prior to randomization.
3. Other Illnesses or Conditions: Participants who have the following comorbidities or gastrointestinal illnesses (GI) are excluded: 3a. Currently diagnosed with Type I or Type II Diabetes 3b. Currently diagnosed with Alcohol Use Disorder and/or Substance Use Disorder 3c. Currently pregnant, planning to become pregnant in the next 9 months, or breastfeeding 3d. History of bariatric or other significant gastrointestinal surgery (e.g., small bowel resection, total colectomy) that has permanently altered GI anatomy or function. Standard appendectomy or cholecystectomy are generally permitted.
3e. Any underlying medical conditions or comorbidities that may confound the assessment of digestive symptoms or the evaluation of the study outcomes 3f. New diagnosis workup planned during study that may change diagnosis/ behavior/ medications (eg. colonoscopy prep or major bowel cleanse, upcoming GI consult that could affect eligibility).
3g. Have a significant illness, disease or condition which, in the opinion of the Principal Investigator, may impact their ability to participate in the study or impact the study outcomes.
4. Participants who are on, plan to initiate, or have recently completed (within the last 3 months) a major restrictive or elimination diet, or a structured weight-loss diet (i.e keto diet, pure carnivore diet, raw food diet, fruitarian diet, liquid diet) during the study period.
5. Use of any antibiotics, antifungals, or antivirals within 2 weeks prior to randomization.
6. Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator 7. Allergy (including alpha-gal syndrome), sensitivity, intolerance, or dietary restriction preventing consumption of investigational product or placebo ingredients 8. Implanted electronic devices, such as a cardiac pacemaker, cochlear implant, or an implanted defibrillator, that might be for use with the bioimpedance scale used in the study (nonelectronic metal implants such as nails, screws, plates, metal braces are OK)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Supplement: Lembas Edge™
Dietary Supplement: Lembas Edge™
Dietary Supplement: Placebo
Lembas Edge™ is a supplement containing a naturally-derived amino acid peptide fragment, which has been previously studied in gastrointestinal applications and demonstrated a well-established safety profile.
A placebo supplement that looks and tastes like the study product but does not any active ingredients.
Change in the Flint Visual Analogue Scale (VAS) score as measured by the change in the appetite assessment score between study product and placebo groups. Baseline period will be compared as well.
The Flint Visual Analogue Scale (VAS) consists of 8 questions scored from 0 to 100. Each question uses a slider where the left and right endpoints represent opposite extremes of hunger, fullness, and specific food cravings.
Time frame: From Baseline to the end of the Product/Placebo Use Period (6 months)
Change in Gastrointestinal Symptom Rating Scale (GSRS) score at the end of 6 months between study product and placebo groups. Baseline period will be compared as well.
The Gastrointestinal Symptom Rating Scale is a 15-item questionnaire that participants complete about digestive symptoms over the past week (reflux, abdominal pain, indigestion, diarrhea and constipation). Each item is scored from 1 (no discomfort) to 7 (very severe discomfort). Higher scores mean worse symptoms.
Time frame: From Baseline to the end of the Product/Placebo Use Period (6 months)
Change from baseline in waist-to-height ratio (WtHR) using provisioned tape at the end of 6 months between study product and placebo groups.
A body tape measure and a height ruler is provided to measure waist circumference and height. A higher ratio means a larger waist relative to height.
Time frame: From Baseline to the end of the Product/Placebo Use Period (6 months)
Change in Ro Allison Indiana Dhurandhar Food Noise (RAID-FN) Inventory score at the end of 6 months between study product and placebo groups, as well as trend over time. Baseline period will be compared as well.
The RAID-FN measure "food noise" intensity and contains 29 items total, ranking items on a 5-point Likert scale.
Time frame: From Baseline to the end of the Product/Placebo Use Period (6 months)
Change from baseline in weight and BMI using a provisioned scale at the end of 6 months between study product and placebo groups
Body mass index is calculated automatically from weight and height captured by a study-provided scale and self-measured height.
Time frame: From Baseline to the end of the Product/Placebo Use Period (6 months)
Assessment of patient satisfaction survey of study experience including design and use of app-based data collection tools
Time frame: End of the Product/Placebo Use Period (Month 6)
Change from baseline in body composition analysis using a provisioned bioimpedance scale at the end of 6 months between study product and placebo groups.
Participants measure body composition (such as body fat, muscle mass and body water) on a study-provided bioimpedance scale.
Time frame: From Baseline to the end of the Product/Placebo Use Period (6 months)
Plan to share: Yes — De-identified individual participant data underlying the results reported in the primary publication will be shared on request. The informed consent form will also be available.
Supporting information: Informed consent form
Time frame: Beginning 6 months after publication of the primary results, for 5 years.
Access criteria: Qualified researchers who submit a methodologically sound proposal to the study contact and sign a data use agreement. Requesters may bear the cost of preparing and transferring the data.
Start is estimated for Nov 2026; primary completion for Jul 2027, 8 months later.
Of 99 interventional studies with no phase under Body Weight Changes, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 8 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lembas